Drugs that contain Eteplirsen
1. Drug name - EXONDYS 51
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(6 years from now) | |
| CN102256606A | SAREPTA THERAPS INC | Method And Means Of Effectivly Hopping Human Duchenne Muscular Dystrophy Gene Exon At Least One Of 43, 46, 50-53 |
May, 2016
(6 years ago) | |
| CN101896186A | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Jul, 2016
(6 years ago) | |
| CN102264903A | SAREPTA THERAPS INC | Method And Means For Effectively Jumping Front Mrna Exon 45 Of Human Duchenne |
Oct, 2028
(6 years from now) | |
| CN102264903B | SAREPTA THERAPS INC | Method And Means For Effectively Jumping Front Mrna Exon 45 Of Human Duchenne |
Oct, 2028
(6 years from now) | |
| CN105641700B | SAREPTA THERAPS INC | Methods And Methods For Combating Muscular Disorders |
Oct, 2028
(6 years from now) | |
| CN105641700A | SAREPTA THERAPS INC | A Muscular Disorder-Resisting Mode And Method |
Oct, 2028
(6 years from now) | |
| EP2206781A2 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP2206781A9 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP2206781B1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP2206781A3 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Apr, 2022
(5 months ago) | |
| EP1766010A1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP1766010B1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2500430A2 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2500430A3 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2500430B1 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP1766010A4 | SAREPTA THERAPS INC | Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof |
Jun, 2025
(2 years from now) | |
| EP2203173B1 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP2614827A2 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP2614827A3 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP3238737A1 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP2614827B1 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP3238737B1 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP2203173A2 | SAREPTA THERAPS INC | Means And Methods For Counteracting Muscle Disorders |
Oct, 2028
(6 years from now) | |
| EP2344637B2 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna |
Jan, 2029
(6 years from now) | |
| EP2344637A1 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna |
Jan, 2029
(6 years from now) | |
| EP2344637B1 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna |
Jan, 2029
(6 years from now) | |
| EP2607484A1 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna |
Jan, 2029
(6 years from now) | |
| EP2607484B1 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of Exon 45 In Duchenne Muscular Dystrophy Pre-Mrna |
Jan, 2029
(6 years from now) | |
| EP2349287A2 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50- 53. |
Mar, 2029
(6 years from now) | |
| EP2349287B1 | SAREPTA THERAPS INC | Methods And Means For Efficient Skipping Of At Least One Of The Following Exons Of The Human Duchenne Muscular Dystrophy Gene: 43, 46, 50- 53. |
Mar, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(2 years from now) | |
| USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(6 years from now) | |
| USRE47769 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(6 years from now) | |
| US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
| US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
| US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(11 years from now) | |
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by correcting a defective gene for dystrophin; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by restoring or increasing functional dystrophin protein production; Treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/2ML (50MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
| 500MG/10ML (50MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.